Evidence map›Paper›PMID 27846906›Full record

ArticleJournal of experimental & clinical cancer research : CR2016

Upregulation of miR-501-5p activates the wnt/β-catenin signaling pathway and enhances stem cell-like phenotype in gastric cancer.

Dongmei Fan, Baoqi Ren, Xiaojun Yang, Jia Liu, Zhengzheng Zhang

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 90 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Stemness signatures reflect prognostic disturbances in gastric cancer.World journal of gastrointestinal oncology · 2025
    Article
  7. Review
  8. Review
  9. Effects ofWorld journal of gastrointestinal oncology · 2024
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Drug Discovery of DKK1 Inhibitors.Frontiers in pharmacology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Dongmei FanDepartment of Gastroenterology, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China. dongmeifan9@sina.com.
Baoqi RenMedical Department of Guangdong Hospital of Traditional Chinese Medicine, Guangzhou, 510405, China.
Xiaojun YangDepartment of Gastroenterology, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Jia LiuThird Affiliated Hospital of Guangzhou Medical College, Guangzhou, China.
Zhengzheng ZhangDepartment of Gastroenterology, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
First Affiliated Hospital of Guangzhou University of Chinese Medicine · CNGuangdong Provincial Hospital of Traditional Chinese Medicine · CNThird Affiliated Hospital of Guangzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundmiRNAs are critical post-transcriptional regulators of gene expression and key mediators of tumourigenesis. miR-501-5p is newly identified to be involved in the tumor progression, but its biological role and mechanism remain largely unknown. This study is aimed to study the role of miR-501-5p in the progression of gastric cancer.

methodsReal-time PCR analysis was used to determine miR-501-5p expression in gastric cancer cell lines, clinical tissues and 112 clinicopathologically characterized gastric cancer specimens. The role of miR-501-5p in maintaining gastric cancer stem cell like phenotype was examined by tumor-sphere formation assay and expression of stem cell markers. Luciferase reporter assay, cellular fractionation and western blot analysis were used to determined that miR-501-5p activated the wnt/β-catenin signaling by directly targeting DKK1, NKD1 and GSK3β.

resultsHerein, our results revealed that miR-501-5p was markedly upregulated in gastric cancer cell lines and clinical tissues. High miR-501-5p levels predicted poor overall survival in gastric cancer patients. Gain-of-function and loss-of-function studies showed that ectopic expression of miR-501-5p enhanced the cancer stem cell-like phenotype in gastric cancer cells. Notably,wnt/β-catenin signaling was hyperactivated in gastric cancer cells that overexpress miR-501-5p, and mediated miR-501-5p-induced cancer stem cell-like phenotype. Furthermore, miR-501-5p directly targeted and suppressed multiple repressors of the wnt/β-catenin signaling cascade, including DKK1, NKD1 and GSK3β. These results demonstrate that miR-501-5p maintains constitutively activated wnt/β-catenin signaling by directly targeting DKK1, NKD1 and GSK3β, which promotes gastric cancer stem cell like phenotype.

conclusionsTaken together, our findings reveal a new regulatory mechanism of miR-501-5p and suggest that miR-501-5p might be a potential target in gastric cancer therapy.

Indexed as

Up-RegulationAdaptor Proteins, Signal TransducingCalcium-Binding ProteinsCarrier ProteinsCell Line, TumorGene Expression Regulation, NeoplasticGlycogen Synthase Kinase 3 betaHumansIntercellular Signaling Peptides and ProteinsMicroRNAsNeoplastic Stem CellsPrognosisStomach NeoplasmsSurvival AnalysisWnt Signaling PathwayAdaptor Proteins, Signal TransducingCalcium-Binding ProteinsCarrier ProteinsDKK1 protein, humanGlycogen Synthase Kinase 3 betaGSK3B protein, humanIntercellular Signaling Peptides and ProteinsMicroRNAsMIRN501 microRNA, humanNKD1 protein, humanCancer stem cellGastric cancermiR-501-5pWnt/β-catenin signaling

Identifiers

PMID27846906
PMCPMC5111270
OpenAlexW2554451832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.